Heron Therapeutics (HRTX) Tops Q4 EPS by 9c, provides guidance

Heron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.07), $0.09 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $34.22 million versus the consensus estimate of $31.14 million.

GUIDANCE:

Heron Therapeutics sees FY2024 revenue of $138-158 million, versus the consensus of $140.9 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• AXT appoints Tracy Liu to its board of directors